Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
News|Articles|December 2, 2021
USP’s Nitrosamine Impurity Standard is Now Official
Author(s)Pharmaceutical Technology Editors
The new General Chapter <1469> “Nitrosamines Impurities” by USP became official on Dec. 2, 2021, in the United States Pharmacopeia—National Formulary.
Advertisement
On Dec. 2, 2021, the United States Pharmacopeia (USP)’s new General Chapter <1469> “Nitrosamines Impurities” became official in the United States Pharmacopeia—National Formulary. By providing guidance on assessing for the presence of nitrosamine, establishing control strategies, and monitoring nitrosamine levels in drug products through ensuring the performance of analytical procedures, the new standard supports both manufacturers and regulators.
In 2018, select angiotensin II receptor blockers that treat high blood pressure and heart failure were found to have nitrosamine impurities. Nitrosamines can potentially cause cancer, depending on the levels and exposure. Since 2018, nitrosamine impurities were found in ranitidine and metformin. As a result, there have been multiple recalls. In addition, regulators and the worldwide industry have worked to reduce or eliminate the presence of these impurities.
In addition to the new standard, USP has developed eight reference standards for various nitrosamine impurities. These highly characterized specimens of the impurities can be used by manufacturers to detect the presence of nitrosamines in their products.
Source:
Advertisement
Related to this article
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Michael Levy, senior vice president, Digital & Innovation, USP, explains the digital supply chain in a preview of his upcoming CPHI Milan panel presentation, The Next Phase of Pharma Supply Chains.
FDA approves tavapadon, first D1/D5 agonist, validating AbbVie's $8.7B Cerevel deal and an October five-strength oral tablet launch.
Merck licenses SciBrunch's preclinical KRAS G12D inhibitor for $2.13B, raising tech transfer and scale-up questions for oral cancer drug development.
Ronald Piervincenzi, USP, urges drugmakers and purchasers to act on supply chain resilience to curb drug shortages and shape better policy.
Advertisement
Advertisement